임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 22:20
논문번호 58
논문제목(영문) The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Kim W
교신저자명 Jeong MH
공동저자명 Kim W, Jeong MH, Kim KH, Sohn IS, Hong YJ, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Cho DL, Kang JC;
게제년월일 2005-10-18
ISSN 0735-1097
Impact Factor 16.503
학술지명 Journal of the American College of Cardiology
서지사항 0집 / 47권 / 5호,   페이지(933 - 938)
요약초록문
(Abstract) 입력		 OBJECTIVES:
This study is a prospective randomized trial investigating clinical outcomes of patients with acute myocardial infarction (AMI) treated with abciximab (ReoPro)-coated stents.
BACKGROUND:
Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the prevention of coronary restenosis.
METHODS:
Ninety-six patients with AMI were randomly allocated into two groups; group I received abciximab-coated stents (n = 48, 57.1 +/- 12.0 years), and group II received bare metal control stents (n = 48, 58.4 +/- 11.6 years).
RESULTS:
At baseline, clinical characteristics, percent diameter stenosis, and minimal luminal diameter were no different between the two groups. One patient in group II had reinfarction and target lesion reintervention during hospital stay. Follow-up coronary angiography was obtained in 77.1% (37 of 48) in group I and 75.0% (36 of 48) in group II. Percent diameter stenosis and late loss were significantly lower in group I than group II (18.9 +/- 5.54% vs. 37.9 +/- 6.25%, p = 0.008; and 0.39 +/- 0.29 mm vs. 0.88 +/- 0.45 mm; p = 0.008, respectively). At follow-up intravascular ultrasound, intrastent lumen area and intrastent neointimal hyperplasia (NIH) area were 5.4 +/- 1.8 mm2 and 2.2 +/- 1.5 mm2, respectively, in group I and 4.3 +/- 1.6 mm2 and 3.4 +/- 1.8 mm2, respectively, in group II (p = 0.045). And, in-stent restenosis rate was lower in group I than group II (p = 0.011 and p = 0.008, respectively). During 1-year follow-up, two patients in group II (4.1%) had AMI, whereas no patient in group I suffered AMI. Target lesion revascularization and total major adverse cardiac events rates were relatively lower in group I compared with those in group II (10.4% [5 of 48] vs. 20.8% [10 of 48], p = 0.261, and 10.4% vs. 25.0%, p = 0.107, respectively).
파일  C58.+J+Am+Coll+Cardiol.+2006;47(5)933-938..pdf (93.3K) DATE : 2021-05-21 16:40:24